Recombinant allergens The present and the future

被引：25
作者：
Jutel, Marek [1 ]
Solarewicz-Madejek, Katarzyna [1 ]
Smolinska, Sylwia [1 ]
机构：
[1] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2012年 / 8卷 / 10期
关键词：
allergy; allergen-specific immunotherapy; recombinant allergens; hypoallergens; vaccines; HOUSE-DUST MITE; BIRCH POLLEN ALLERGEN; COMPONENT-RESOLVED DIAGNOSTICS; T-CELL PEPTIDES; GRASS-POLLEN; CROSS-REACTIVITY; FOLLOW-UP; IMMUNOTHERAPY; CAT; EPITOPE;
D O I：
10.4161/hv.22064
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.
引用
收藏
页码：1534 / 1543
页数：10
相关论文
共 72 条
[31]   Peptide immunotherapy for allergic diseases [J].
Larche, M. .
ALLERGY, 2007, 62 (03) :325-331
[32]   Peptide and Recombinant Immunotherapy [J].
Larche, Mark .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2011, 31 (02) :377-+
[33]   A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination [J].
Linhart, B ;
Hartl, A ;
Jahn-Schmid, B ;
Verdino, P ;
Keller, W ;
Krauth, MT ;
Valent, P ;
Horak, F ;
Wiedermann, U ;
Thalhamer, J ;
Ebner, C ;
Kraft, D ;
Valenta, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (05) :1010-1016
[34]   The safety and efficacy of ALLERVAX CAT in cat allergic patients [J].
Maguire, P ;
Nicodemus, C ;
Robinson, D ;
Aaronson, D ;
Umetsu, DT .
CLINICAL IMMUNOLOGY, 1999, 93 (03) :222-231
[35]   STUDIES ON ALLERGOIDS FROM NATURALLY-OCCURRING ALLERGENS .3. PREPARATION OF RAGWEED POLLEN ALLERGOIDS BY ALDEHYDE MODIFICATION IN 2 STEPS [J].
MARSH, DG ;
NORMAN, PS ;
ROEBBER, M ;
LICHTENSTEIN, LM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1981, 68 (06) :449-459
[36]   Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy [J].
Martinez-Gomez, J. M. ;
Johansen, P. ;
Rose, H. ;
Steiner, M. ;
Senti, G. ;
Rhyner, C. ;
Crameri, R. ;
Kuendig, T. M. .
ALLERGY, 2009, 64 (01) :172-178
[37]   Immunotherapy with peptides [J].
Moldaver, D. ;
Larche, M. .
ALLERGY, 2011, 66 (06) :784-791
[38]   Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom [J].
Müller, U ;
Akdis, CA ;
Fricker, M ;
Akdis, M ;
Blesken, T ;
Bettens, F ;
Blaser, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (06) :747-754
[39]   Vaccination with genetically engineered allergens prevents progression of allergic disease [J].
Niederberger, V ;
Horak, F ;
Vrtala, S ;
Spitzauer, S ;
Krauth, MT ;
Valent, P ;
Reisinger, J ;
Pelzmann, M ;
Hayek, B ;
Kronqvist, M ;
Gafvelin, G ;
Grönlund, H ;
Purohit, A ;
Suck, R ;
Fiebig, H ;
Cromwell, O ;
Pauli, G ;
van Hage-Hamsten, M ;
Valenta, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14677-14682
[40]   Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome [J].
Niederberger, Verena ;
Reisinger, Jurgen ;
Valent, Peter ;
Krauth, Maria-Theresa ;
Pauli, Gabrielle ;
van Hage, Marianne ;
Cromwell, Oliver ;
Horak, Friedrich ;
Valenta, Rudolf .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (04) :1013-1016
12345678